Post by Javier Cerda Infante, PhD, MBA

Pharma Deals 2026!! 💊 💸 Every time I share how we think about a potential pharma exit for Environ, some people look at me like: “Are those numbers really possible?” And the answer is yes... In pharma, when a technology can solve a major problem and become a blockbuster, the numbers stop looking big. But there is something people often forget: The deal is not the hardest part. The hardest part is surviving long enough to get there. It is finding support when you are still building the evidence. When the scientific risk is still high. When no big pharma has validated you yet. When there is no headline saying that “it was obvious.” That is the moment where you truly see who believes in innovation early, and who only wants to be there once the story is already in the newspaper. At Environ, we are building from Chile a technology aimed at one of the biggest unsolved challenges in cancer: metastasis. We know the path is difficult. But we also know that great biotech stories do not start with a billion-dollar deal. They start much earlier. With science. With conviction. And with people willing to believe before it becomes obvious. #Biotech #Pharma #Oncology #CancerResearch #VentureCapital #Startups #LifeSciences #Environ